Impact Factor
4.20
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
5.26
3,601 total citations
h5-index
60
h5 depth signal
Cited share
81.1%
605 of 746
Total citations
3,601
Citation footprint
Metric signal
4.98
External metric anchor
Self-citation
1.2%
45 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
Japan
2,246
China
1,342
United States
280
South Korea
80
Germany
26
Citing Fields of Research
Oncology
1,063
Cancer & Development
890
Immunology
767
Lung Cancer
515
Cancer, Autophagy & Apoptosis
510
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
7,732
Articles tracked across the journal lifetime
Indexed publication set
746
605 cited publications
Last 12 months
344
28.7 publications/month
Open access share
100.0%
344 OA publications in the last year
Leading citing country
Japan
2,246 citing publications
Leading citing field
Oncology
1,063 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v94n1, Jan. 2003-
v79n1, 1988-
Active Coverage
Active Coverage
Research Focus & Classification
Indexed Subjects
Immunology
Oncology
Lung Cancer
Cancer & Development
Noncoding RNA
Cancer, Autophagy & Apoptosis
Issuing & Sponsoring Bodies
Contributor
Nihon Gan Gakkai
Broad Categories
Neoplasms
Immunology
Cancer, Autophagy & Apoptosis
Noncoding RNA
Lung Cancer
Cancer & Development
Immunotherapy
Genetics & Genomics
MeSH Descriptors
Neoplasms
Research
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1111/cas.70565
Open DOI
Advances in the Role of Chemokines in Microwave Ablation‐Based Combinatorial Immunotherapy
Immunotherapy enhances antitumor immunity to eliminate malignant cells and has great potential to prevent tumor recurrence and distant metastasis. In addition to direct tumor destruction, microwave ablation (MWA) remodels the tumor immun...
02
DOI 10.1111/cas.70568
Open DOI
Distinct Clinicogenomic Contexts of BRAF ‐Altered Gliomas and Glioneuronal Tumors: A Nationwide Real‐World Study
BRAF alterations occur across diverse gliomas and glioneuronal tumors, but their alteration‐specific clinicogenomic contexts in real‐world cancer genomic profiling cohorts remain incompletely characterized. We analyzed BRAF ‐altered brai...
03
DOI 10.1111/cas.70557
Open DOI
CDK4 /6 Inhibitors and Curcumin Synergistically Suppress HER2 − Breast Cancer via Lethal ROS and Inhibition of Metastasis
CDK4/6 inhibitors represent a key therapy for HR+/HER2− breast cancer, yet resistance and limited efficacy in triple‐negative breast cancer (TNBC) remain significant challenges. Using a self‐established drug combination prediction platfo...
04
DOI 10.1111/cas.70567
Open DOI
Evolution of CAR ‐T Therapy: Functional Engineering, Manufacturing Innovation, and Future In Vivo Strategies
Chimeric antigen receptor (CAR)‐T cell therapy has transformed the treatment of hematologic malignancies and established a new paradigm for engineered cellular immunotherapy. However, its broader clinical application remains constrained ...
05
DOI 10.1111/cas.70563
Open DOI
The Serotonergic and Cholinergic Signaling Pathways Drive Gastric Precancerous Lesions and Its Potential Mechanism
Gastric cancer (GC) is a leading lethal malignancy globally. Gastric precancerous lesion (GPL) represents a critical step in GC, but its neural regulatory mechanisms remain largely unclear. We combined bioinformatics, patch‐clamp recordi...
06
DOI 10.1111/cas.70562
Open DOI
Real‐World Germline Variant Landscape and Clinical Management in Korean Patients Tested for Suspected Hereditary Cancer
Germline pathogenic/likely pathogenic (P/LP) variants inform cancer treatment and prevention, yet real‐world detection patterns and downstream clinical management remain poorly characterized in East Asian hereditary cancer cohorts. This ...
07
DOI 10.1111/cas.70564
Open DOI
Distinct Clinical Features of Multiple Myeloma With t(11;14): A Post Hoc Analysis of JSH ‐ MM ‐15 Study
T(11;14) (q13;q32) occurs in approximately 15%–25% of multiple myeloma (MM) cases and has traditionally been regarded as a standard cytogenetic risk factor. However, recent evidence suggests that MM with t(11;14) exhibits heterogeneous b...
08
DOI 10.1111/cas.70554
Open DOI
A Novel Plasma Biomarker hsa_circ_0080018 Drives DLBCL Progression via M2 Polarization of Tumor‐Associated Macrophages
Noncoding RNAs, including circular RNAs (circRNAs), have been demonstrated to play vital roles in tumorigenesis. Uncovering the functions of circRNAs in tumorigenesis and their underlying regulatory mechanisms may suggest new approaches ...
09
DOI 10.1111/cas.70555
Open DOI
Spatial Atlas of Small Cell Lung Carcinoma Reveals Intratumoral Tumor‐State Heterogeneity and an MMP12 + Macrophage Niche
Small‐cell lung carcinoma (SCLC) is a highly aggressive tumor with a dismal prognosis among lung cancers. Treatment is failing because of primary or rapidly developing secondary resistance. Recent molecular studies have suggested four SC...
10
DOI 10.1111/cas.70558
Open DOI
Angiogenic and Stromal Remodeling Associated With Aggressive Fibrosarcomatous Dermatofibrosarcoma Protuberans
Although collagen type 1 alpha 1 ( COL1A1 )–platelet‐derived growth factor B‐chain ( PDGFB ) gene fusion is a characteristic driver alteration in fibrosarcomatous dermatofibrosarcoma protuberans (FS‐DFSP), an aggressive DFSP variant, the...
Bibliographical & Catalog Notes
Title from cover.
Latest issue consulted: Vol. 94, no. 2 (Feb. 2003).
Print issues ceased with v.102, no.12 (2011).
Also issued online.
Official journal of the Japanese Cancer Association.